Grants for Public housing authorities - Education

This funding opportunity supports U.S. research institutions and organizations in developing and testing housing interventions that improve health outcomes and reduce disparities for populations facing housing instability, particularly among older adults and marginalized communities.

This funding opportunity provides financial support to organizations that develop and implement person-centered, trauma-informed care services for Holocaust survivors and other older adults with trauma histories, along with their family caregivers.

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

This grant provides funding to support late-stage Ph.D. students from diverse backgrounds in completing their dissertation research and transitioning into postdoctoral positions in biomedical research.

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. Frequently Asked Questions for NOT-HL-23-083 General Questions Q: What is the purpose of the Notice of Special Interest (NOSI) NOT-HL-23-083? The NOSI on Assessing Real-World Effectiveness and Implementation of Telehealth-Guided Provider-to-Provider Communication among Rural Communities (NOT-HL-23-083) aims to support research that generates evidence on the real-world effectiveness of telehealth collaboration among healthcare providers for consultation, second opinions, and other purposes, referred to as provider-to-provider telehealth (PPT). The NOSI is intended to support the use of telehealth interventions and tools for the prevention, management and treatment of heart, lung, blood, and sleep conditions, as well as cancer, in rural communities. Q: Are foreign applications allowed under this NOSI? Yes. Non-domestic entities (Foreign Institutions) and Non-domestic components of U.S. Organizations are eligible to apply under the Notice of Funding Opportunities (NOFOs) relevant to this NOSI (PA-20-185; PAR-22-105; PAR-21-035; PAR-21-341) – additional information regarding eligibility is available in Section III. Eligibility Information of each NOFO. Q: How is “rural” defined for the purposes of this NOSI? Different definitions of “rural” are used by various entities for different purposes. Rurality can be conceptualized based on administrative boundaries, land-use patterns, or economic influence; can reflect several different dimensions, such as population density, population size, and degree of remoteness; and can be delineated at different spatial scales (e.g., zip code, county, census district). Applicants should operationalize “rural” in the way that best serves the aims of their study. However, applicants should clearly state how they are defining rural in their application and provide a justification for the criteria they are using. A few widely used classification systems for defining rural and urban areas are provided below. Additionally, the Health Resources and Services Administration (HRSA) provides a tool on their website that enables users to see whether a specified geographic area is considered “rural” for the purposes of HRSA Rural Health Grant eligibility: https://data.hrsa.gov/tools/rural-healthexternal link. This may be a good starting point for assessing whether an area of interest might be considered “rural”. Census Bureau Urban-Rural Classificationsexternal link - The Census Bureau delineates urban areas by applying specified criteria to the decennial census and other data. For the 2020 Census, an urban area comprises a densely settled core of census blocks that meet minimum housing unit density and/or population density requirements of having at least 2,000 housing units or a population of at least 5,000. This includes adjacent territory containing non-residential urban land uses. Rural areas encompass all population, housing, and territory not included within an urban area. National Center for Health Statistics (NCHS) Urban-Rural Classification Scheme for Countiesexternal link – NCHS has developed a six-level urban-rural classification scheme for U.S. counties and county-equivalent entities. The scheme is based on the Office of Management and Budget’s (OMB) delineation of metropolitan statistical areas (MSA) and micropolitan statistical areas, as well as Vintage postcensal estimates of the resident U.S. population. The scheme has two levels nonmetropolitan counties. USDA Rural Urban Continuum Codes (RUCC)external link - Rural-Urban Continuum Codes are a 9-level classification scheme that categorizes metropolitan counties by the population size of their metro area, and nonmetropolitan counties by their degree of urbanization and adjacency to a metro area. USDA Rural Urban Commuting Area (RUCA) Codesexternal link - RUCA codes categorize census tracts based on measures of population density, urbanization, and daily commuting patterns. This classification system consists of 10 levels that delineate metropolitan, micropolitan, small town, and rural commuting areas based on the size and direction of the primary (largest) commuting flows. These 10 codes are further subdivided based on secondary commuting flows. USDA Urban Influence Codesexternal link (UIC) – Urban influence codes are a 12-level classification scheme that distinguishes metropolitan counties by the population size of their metro area, and nonmetropolitan counties by the size of the largest city or town and proximity to metro and micropolitan areas. There are two metro and ten nonmetro categories. Frontier and Remote Area (FAR) Codesexternal link – Developed by the USDA Economic Research Service, Frontier and Remote Area codes are based on ZIP-codes. The term "frontier and remote" is used to describe territory characterized by some combination of low population size and high geographic remoteness. FAR areas are defined in relation to the time it takes to travel by car to the edges of nearby Urban Areas (UAs)external link. Four levels are necessary because rural areas experience degrees of remoteness at higher or lower population levels that affect access to different types of goods and services. Q: My project focuses on “direct-to-consumer/ direct-to-patient” telehealth, would it still be responsive to this NOSI? No. This NOSI focuses on “provider-to-provider” telehealth (PPT), which is a telehealth modality that fosters collaboration among healthcare providers for consultation, second opinions, and other purposes. Please refer to the “Background” section of the NOSI for some examples of PPT in heart, lung blood, sleep and cancer conditions. Q. My university/institution is located in an urban area, would I still qualify for this NOSI? There is no restriction regarding the location of the Principal Investigator’s university, institution, or center and if it is in an urban or rural area. The limiting factor is the population of interest. The focus of this NOSI is the use of provider-to-provider telehealth (PPT) to benefit rural communities. For the definition of rural areas, please refer to the previous questions “How is “rural” defined for the purposes of this NOSI?” Q. One of the components of my research involves a center or hospital located in an urban center/hospital, would I still qualify for this NOSI? It depends. The focus of this NOSI is the use of provider-to-provider telehealth (PPT) to benefit rural communities. As such, considering a hub-and-spoke telehealth model, the healthcare providers who require consultation and their patients (spoke component) must be in a rural area, assuring that the benefited population served by the PPT intervention is rural. Example 1: If both communicating sides of providers (hub and spoke) are in urban areas, it is not responsive to this NOSI. Example 2: If the provider receiving the consultation or training (spoke) is in a rural area, and the consulted team (hub or hub-less provider) is in an urban area, it is responsive to this NOSI, given that the population of interest benefitted by the PPT intervention is still in a rural area. For the definition of rural areas, please refer to the previous questions “How is “rural” defined for the purposes of this NOSI?” Q. Is the NOSI restricted to telemedicine between physicians? No. The focus of the NOSI is not just telemedicine, but telehealth, which goes beyond the communication between physicians, and would include a series of healthcare providers, allied health providers, and their teams. For some examples, please refer to the “ Background” section of the NOSI. Q: What are some of the research examples that might be responsive to this NOSI? There are a series of research projects that might be of interest for this NOSI. For some examples, please refer to the ones listed in the “Selected Research Examples ” section of the NOSI. Please be aware that these are meant to illustrate some of the projects of interest for this NOSI, and other research projects not exemplified here might still be of interest. Investigators are encouraged to reach out to the Scientific and Research Contacts listed in the NOSI to discuss their research ideas and their relevance to the NOSI as well as institute funding priorities. Q. Who do I contact for more information from specific participating Institutes, Centers, and Offices? To whom should I direct my questions regarding this NOSI? To access the complete list of contacts, please refer to the “Inquiries” Section of the NOSI, which includes Scientific and Research Contacts and Financial/Grants Management Contacts. For programmatic questions at NHLBI, please contact Dr. Fernando P. Bruno [email protected]:, for programmatic questions at NCI, please contact Dr. Robin C. Vanderpool [email protected]:. If you have submission questions, please contact the eRA Service Desk. Application Preparation and Submission Questions Q: NHLBI and NCI are collaborating on this NOSI. If an applicant has a proposal that is relevant to both cancer and to heart, lung, blood, and sleep conditions, which institute will the application be assigned to? Applicants are advised to make use of the Assignment Request Form to request the institute they would prefer to act as the “Awarding Component.” These requests are taken into consideration. Applicants are further advised to consider the institute they plan to choose on the Assignment Request Form when framing their specific aims. The Awarding Component Section of the PHS Assignment Request Form * All assignment suggestions will be considered; however, not all assignment suggestions can be honored. Applications are assigned based on relevance of the application to an individual awarding component mission and scientific interests in addition to administrative requirements. * Applicants may enter up to three preferences for primary assignment in the boxes in the "Suggested Awarding Component(s)" row. Note: the application will be assigned based on the most appropriate match between it, the terms of the FOA, and the mission of each possible awarding component, with your preference(s) taken into consideration when possible. Applicants do not need to make entries in all three boxes of the "Awarding Component Assignment Suggestions" section. Q: If a proposal has aims that might be responsive to more than one eligible Notice of Funding Opportunity (NOFO) – should an investigator submit an application that is targeted at two different eligible funding opportunities, or separate those aims into two different applications and submit one to each corresponding NOFO? Each application in response to this NOSI must target only one of the eligible NOFOs. An applicant can elect to submit two different applications to two different NOFOs as long as the specific aims are sufficiently distinct. If the Division of Receipt and Referral determines there is significant overlap between the two applications, the applicant could be asked to withdraw one of them.

This funding opportunity is designed to support small-scale research projects at health professional and graduate schools that have limited NIH funding, helping to enhance research capabilities and engage students in meaningful research experiences.

This program provides funding to various organizations to expand high-speed internet access in underserved areas of Illinois, focusing on improving connectivity for schools, libraries, and health facilities.

This funding opportunity supports researchers exploring the use of microorganisms for innovative cancer therapies and imaging techniques, particularly in areas where traditional treatments fall short.

This funding opportunity supports research collaborations between academic institutions and community behavioral health organizations to improve outpatient mental health and substance use treatment through evidence-based practices.

This funding opportunity supports small research teams in developing innovative biomedical technologies that address critical health challenges and improve healthcare accessibility.

This program will support projects to identify and characterize factors associated with gender-affirming hormone therapy (GAHT) that may impact/contribute significantly to the prevention and treatment of HIV and/or co-infections with other sexually transmitted infections (STI)s in transgender individuals. For this funding opportunity GAHT is defined as a medical intervention, including but not limited to estrogen and/or testosterone treatment, that results in acquisition of secondary sex characteristics that align with an individual's gender identity. A growing body of data indicates that GAHT may impact the effectiveness and implementation of biomedical HIV prevention or treatment strategies and/or co-infections with other STIs. A number of factors in transgender populations present research challenges including variability in GAHT regimens, use of auxiliary drugs during GAHT care, access to participants, and access to existing cohorts, datasets, and samples. Consideration of appropriate controls, including cis-gender men and women is also a barrier. Recent studies demonstrating recruitment and retention of participants undergoing GAHT provide the opportunity to build on those studies and provide confidence that these critical studies are feasible.Letter of Intent Due Date(s) 30 days prior to the application due date

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying those patients at high risk of PDAC (because of genetic factors or presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens and data within the Consortium. The other scientific component of the PCDC will be the Management and Data Coordination Unit (MDCU). The PCDC-MDCU will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort.

This funding opportunity supports innovative research to improve personalized probiotic treatments by studying individual biological factors that influence how people respond to probiotics.

This funding opportunity supports researchers in developing new medications to prevent and treat opioid and stimulant use disorders and overdose, with a focus on advancing promising treatments towards FDA approval.

This funding opportunity supports innovative research using microbes to improve cancer diagnosis and treatment, targeting researchers and institutions focused on microbiology, oncology, and immunology.

This funding opportunity supports innovative research projects that explore how sex hormones affect the relationship between HIV and substance use disorders, targeting scientists and institutions focused on molecular biology and addiction.

This funding opportunity supports researchers in developing innovative informatics methods and algorithms to improve cancer research and management across various areas, including diagnosis, treatment, and prevention.

This funding opportunity supports a variety of organizations and individuals in Togo to create projects that strengthen cultural ties and promote mutual understanding between the United States and Togo, focusing on themes like peace, democracy, and economic growth.

This grant provides funding for researchers to explore the interactions between the brain and immune system in the context of HIV and substance use disorders, aiming to identify new therapeutic targets and improve understanding of related neurological issues.

This funding opportunity supports researchers from various fields in developing innovative methods to study brain changes over time, focusing on both healthy individuals and those with specific cognitive or emotional challenges.